{"schema_version":"1.0","type":"article","title":"何時果斷放棄新藥臨床試驗開發？","url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.md","lang":"zh-Hant","date":"2026-04-10","publish_at":"2026-04-10T10:30:00+08:00","updated_at":"2026-04-10","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"新藥開發最難的，往往不是立項那一天，而是明明已經看見風險，卻仍不願按下停止鍵的那一天。每一個研發專案開始時，幾乎都帶著同樣的想像：要做到 first-in-class、要走到 pivotal study、要送件、要上市、要成為下一個成長引擎。然而現實比願景殘酷得多。","key_points":[],"facts":[],"sections":["如何優雅地終止一個新藥開發案：真正成熟的藥廠，懂得在對的時點收手","先定義成功，才有資格優雅地收手","真正難的，從來不是科學，而是人性","真正有效的 stage gate，不是行政流程，而是誠實審判","最該停的，常常不是完全沒活性的案子","臨床階段最難停的，是那種「不是沒效，只是不夠好」的藥","真正優雅的終止，不一定是關掉，而可能是換人做","最後真正決定能不能停的，還是文化"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Ninety percent of clinical drug development fails despite implementation of many successful strategies, which raised the question whether certain aspects in target validation and drug optimization are overlooked? Current drug optimization overly ...","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","source":"","date":"","url":""},{"title":"In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry averages in 2005-2010. A cornerstone of the revised strategy was to focus decision-making","source":"","date":"","url":""},{"title":"pubmed.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5478920/","source":"","date":"","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5478920/"},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Decades of research have demonstrated that a variety of cognitive biases can affect our judgment and ability to make rational decisions in personal and professional environments. The lengthy, risky, and costly nature of pharmaceutical research and ...","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density","source":"","date":"","url":""},{"title":"AbstractContext:. Ronacaleret, a calcium-sensing receptor antagonist that stimulates PTH release from the parathyroid glands, was evaluated as an oral oste","source":"","date":"","url":""},{"title":"academic.oup.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"Lock","source":"","date":"","url":""},{"title":"Model‐informed drug development (MIDD) has been increasingly applied to guide decision‐making, ameliorate efficiency, and enhance the likelihood of successful trials. The development of ligelizumab, a humanized anti‐IgE monoclonal antibody, in ...","source":"","date":"","url":""},{"title":"pmc.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"Company Overview","source":"Roivant","date":"","url":""},{"title":"https://www.roivant.com/about/company","source":"","date":"","url":"https://www.roivant.com/about/company"},{"title":"www.roivant.com","source":"","date":"","url":""},{"title":"[8]:","source":"","date":"","url":""},{"title":"Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical - Merck.com","source":"","date":"","url":""},{"title":"CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and","source":"","date":"","url":""},{"title":"www.merck.com","source":"","date":"","url":""},{"title":"[9]:","source":"","date":"","url":""},{"title":"www.astrazeneca.com","source":"","date":"","url":""},{"title":"https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/transforming-astrazenecas-rd-productivity.html","source":"","date":"","url":"https://www.astrazeneca.com/what-science-can-do/topics/disease-understanding/transforming-astrazenecas-rd-productivity.html"},{"title":"www.astrazeneca.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-01.webp"},{"alt":"Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-02.webp"},{"alt":"Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-03.png"},{"alt":"Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 4）","url":"https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-04.png"},{"alt":"Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 5）","url":"https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-05.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-10）。何時果斷放棄新藥臨床試驗開發？。https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-10-dcard-261269760-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}